News
Prelude Therapeutics
PRLD · NASDAQ
$3.53+$0.14 (+4.13%)TodayMarket closed ·
Prev close $3.39
Latest news
- Press releaseGlobe Newswire
Prelude Announces Clinical Trial Collaboration and Supply Agreement with Lilly to Evaluate KAT6A Selective Degrader PRT13722 in Combination with Verzenio® and Inluriyo® in Patients with HR+/HER2- Breast Cancer
- Press releaseGlobe Newswire
Prelude Therapeutics Receives FDA Clearance of Investigational New Drug (IND) Application for PRT13722, Its First-in-Class Oral KAT6A Selective Degrader
- News
12 Health Care Stocks Moving In Thursday's Intraday Session
- Press releaseGlobe Newswire
Prelude Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
- News
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
- NewsAvi Kapoor
Dave and Buster's Reports Downbeat Q1 Earnings, Joins Alvotech And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
- Press releaseGlobe Newswire
Prelude Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
- News
12 Health Care Stocks Moving In Thursday's After-Market Session
- Press releaseGlobe Newswire
Prelude Therapeutics Announces Pricing of $90.0 Million Underwritten Offering
- News
Prelude Therapeutics Announces Presentation Of New Preclinical Data From PRT13722 For The Treatment Of Hormone Receptor Positive/Human Epidermal Growth Factor Receptor 2 Breast Cancer, And Believes That PRT13722 Is A Highly Differentiated, First-In-Class, Orally Bioavailable, Potent And Highly-selective Kat6A Degrader
- Press releaseGlobe Newswire
Prelude Therapeutics Presents Preclinical Data from Development Candidate, PRT13722, a First-in-Class, Orally Bioavailable, Potent and Highly Selective KAT6A Degrader at American Association for Cancer Research (AACR) Annual Meeting 2026
- News
12 Health Care Stocks Moving In Thursday's Intraday Session
- Press releaseGlobe Newswire
Prelude Therapeutics Announces the Appointment of Charles Morris, M.D. as Chief Medical Officer
- Press releaseGlobe Newswire
Prelude Therapeutics Announces Acceptance of Preclinical Abstract for PRT13722, a First-in-Class Oral KAT6A Selective Degrader at the 2026 AACR Annual Meeting
- News
Prelude Therapeutics Earnings Report: Q4 Overview
- Press releaseGlobe Newswire
The $71 Billion Cancer Shift: Why The FDA Is Speeding Up
- Press releaseGlobe Newswire
Cancer Drug Developers Secure Regulatory Clarity as FDA Reshapes Approval Standards
- Press releaseGlobe Newswire
PRLD Investors Have Opportunity to Join Prelude Therapeutics Incorporated Fraud Investigation with the Schall Law Firm
- Press releasePRNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Prelude Therapeutics Incorporated - PRLD
- Press releaseGlobe Newswire
PRLD Investors Have Opportunity to Join Prelude Therapeutics Incorporated Fraud Investigation with the Schall Law Firm
- Press releaseGlobe Newswire
Targeted Cancer Therapies Gain Momentum as Precision Market Surges Past $106B
- News
12 Health Care Stocks Moving In Thursday's After-Market Session
- Press releaseBusiness Wire
PRLD Investors Have Opportunity to Join Prelude Therapeutics Incorporated Fraud Investigation With the Schall Law Firm
- News
12 Health Care Stocks Moving In Tuesday's After-Market Session
- News
12 Health Care Stocks Moving In Tuesday's Intraday Session
- NewsAvi Kapoor
Dow Dips Over 400 Points; Pfizer Earnings Top Estimates
- News
Market-Moving News for November 4th
- NewsAvi Kapoor
UBS Posts Upbeat Earnings, Joins Victoria's Secret, Performance Food Group, Kellanova And Other Big Stocks Moving Higher On Wednesday
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.